Publicacións en colaboración con investigadores/as de Complejo Asistencial Universitario de León (9)

2023

  1. Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)

    Cancer Treatment and Research Communications, Vol. 37

2022

  1. Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study

    Cancers, Vol. 14, Núm. 23

  2. SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA

    Future Oncology, Vol. 18, Núm. 34, pp. 3791-3800

2020

  1. Fatty acid intake and breast cancer in the Spanish multicase–control study on cancer (MCC-Spain)

    European Journal of Nutrition, Vol. 59, Núm. 3, pp. 1171-1179

2019

  1. Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

    Breast Cancer Research, Vol. 21, Núm. 1

  2. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study

    Breast Journal, Vol. 25, Núm. 2, pp. 219-225

2018

  1. Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): An open-label, randomized, three-arm, multicenter, window-of-opportunity study

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii64

  2. Experience with eribulin in HR+/HER2- metastatic breast cancer, including a male

    Future Oncology, Vol. 14, Núm. 7s, pp. 5-12

2014

  1. Aldehyde dehydrogenases in early stage lung cancer: nuclear expression

    Clinical and Translational Oncology, Vol. 16, Núm. 10, pp. 931-934